David Risinger
Stock Analyst at Leerink Partners
(4.47)
# 335
Out of 5,124 analysts
178
Total ratings
66.33%
Success rate
14.31%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Outperform | $305 → $355 | $384.32 | -7.63% | 6 | Feb 4, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Outperform | $54 → $60 | $61.99 | -3.21% | 5 | Jan 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $456 → $525 | $477.92 | +9.85% | 6 | Dec 29, 2025 | |
| ROIV Roivant Sciences | Maintains: Outperform | $29 → $32 | $25.82 | +23.93% | 6 | Dec 15, 2025 | |
| XOMA XOMA Royalty | Maintains: Outperform | $58 → $45 | $24.86 | +81.01% | 1 | Dec 11, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Outperform | $886 → $1,104 | $1,058.18 | +4.33% | 17 | Nov 10, 2025 | |
| IMA ImageneBio | Initiates: Outperform | $30 | $7.02 | +327.66% | 1 | Oct 24, 2025 | |
| HALO Halozyme Therapeutics | Upgrades: Market Perform | $70 | $81.23 | -13.82% | 4 | Oct 14, 2025 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $169 → $153 | $239.99 | -36.25% | 4 | May 13, 2025 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $762 → $834 | $785.51 | +6.17% | 9 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $206 | $223.43 | -7.80% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $69 | $24.37 | +183.14% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $12.73 | +25.69% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $33.05 | +33.13% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $106 → $153 | $56.15 | +172.48% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $10 | $20.48 | -51.17% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $49.73 | -5.49% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $23.49 | -53.17% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $152.50 | -40.33% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $27.22 | +76.34% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $8.21 | +350.67% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $165.50 | +6.34% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $14.58 | +9.74% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $14.64 | +207.38% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $5.88 | +495.24% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $25.20 | +62.70% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $127.42 | +36.56% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $44.65 | +14.22% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $34.69 | -76.94% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $121.93 | -27.01% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $14.52 | -79.34% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $34.91 | -54.17% | 9 | Apr 2, 2020 |
Amgen
Feb 4, 2026
Maintains: Outperform
Price Target: $305 → $355
Current: $384.32
Upside: -7.63%
Bristol-Myers Squibb Company
Jan 13, 2026
Maintains: Outperform
Price Target: $54 → $60
Current: $61.99
Upside: -3.21%
Vertex Pharmaceuticals
Dec 29, 2025
Maintains: Outperform
Price Target: $456 → $525
Current: $477.92
Upside: +9.85%
Roivant Sciences
Dec 15, 2025
Maintains: Outperform
Price Target: $29 → $32
Current: $25.82
Upside: +23.93%
XOMA Royalty
Dec 11, 2025
Maintains: Outperform
Price Target: $58 → $45
Current: $24.86
Upside: +81.01%
Eli Lilly and Company
Nov 10, 2025
Upgrades: Outperform
Price Target: $886 → $1,104
Current: $1,058.18
Upside: +4.33%
ImageneBio
Oct 24, 2025
Initiates: Outperform
Price Target: $30
Current: $7.02
Upside: +327.66%
Halozyme Therapeutics
Oct 14, 2025
Upgrades: Market Perform
Price Target: $70
Current: $81.23
Upside: -13.82%
Johnson & Johnson
May 13, 2025
Downgrades: Market Perform
Price Target: $169 → $153
Current: $239.99
Upside: -36.25%
Regeneron Pharmaceuticals
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $785.51
Upside: +6.17%
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $223.43
Upside: -7.80%
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $24.37
Upside: +183.14%
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $12.73
Upside: +25.69%
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $33.05
Upside: +33.13%
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $56.15
Upside: +172.48%
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $20.48
Upside: -51.17%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $49.73
Upside: -5.49%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $23.49
Upside: -53.17%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $152.50
Upside: -40.33%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $27.22
Upside: +76.34%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $8.21
Upside: +350.67%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $165.50
Upside: +6.34%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $14.58
Upside: +9.74%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $14.64
Upside: +207.38%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $5.88
Upside: +495.24%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $25.20
Upside: +62.70%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $127.42
Upside: +36.56%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $44.65
Upside: +14.22%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $34.69
Upside: -76.94%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $121.93
Upside: -27.01%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $14.52
Upside: -79.34%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $34.91
Upside: -54.17%